Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 912345...Last »

General Mills recalls flour over possible link to E. coli outbreak

General Mills Inc issued a voluntary recall of about 10 million pounds of flour, saying it was working with health officials to investigate an outbreak of E. coli that had sickened 38 people in 20 U.S. states.

Read More »

U.S. FDA Approves Once-daily Jentadueto XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes

The U.S. Food and Drug Administration has approved Jentadueto XR (linagliptin and metformin hydrochloride extended-release) tablets for the treatment of type 2 diabetes (T2D) in adults.

Read More »

U.S. Supreme Court rejects patent appeal over Cubicin drug

The U.S. Supreme Court rejected Cubist Pharmaceuticals Inc’s bid to revive four patents for its antibiotic drug Cubicin, paving the way for rival Hospira Inc to introduce a generic version as soon as this year.

Read More »

Daiichi Sankyo to not proceed with lung cancer study

Daiichi Sankyo Co Ltd said it will not proceed with the second part of its late-stage study on the lung cancer drug, patritumab.

Read More »

Amicus’ Fabry disease drug gets European Commission approval

Amicus Therapeutics Inc said the European Commission approved the use of migalastat, its experimental treatment for Fabry disease, an inherited disease that creates pain and burning in the hands and feet.

Read More »

FDA asks Teva Pharmaceutical for further study on Huntington drug

Israel-based Teva Pharmaceutical Industries said on Tuesday approval for a drug to treat chorea stemming from Huntington disease has been held up by U.S. regulators seeking further blood study.

Read More »

Intercept Pharma’s Liver Drug Wins Accelerated Approval by the FDA

FDA granted accelerated approval to Ocaliva, the first new medicine for primary biliary cholangitis in nearly 20 years.

Read More »

FDA Approves Once-Monthly MS Drug Zinbryta

A once-per-month injection for MS developed by Biogen and AbbVie received FDA approval.

Read More »

Jazz Pharma Pays $1.5 Billion for Celator Pharma

Jazz Pharmaceuticals struck a deal to acquire Celator Pharmaceuticals and its promising leukemia drug for $1.5 billion.

Read More »

Roche’s MabTherea shot gets EU OK for chronic lymphocytic leukemia

Drugmaker Roche has received European approval for an injectable form of antibody therapy MabThera for people with chronic lymphocytic leukemia.

Read More »

EU approves first gene therapy for children

The world’s first life-saving gene therapy for children, developed by GlaxoSmithKline and Italian scientists, was approved for sale in Europe.

Read More »

U.S. sees first case of bacteria resistant to all antibiotics

U.S. health officials reported the first case in the country of a patient with an infection resistant to all known antibiotics, and expressed grave concern that the superbug could pose serious danger for routine infections if it spreads.

Read More »

Thermo Fisher Scientific Antes Up $4.2 Billion for FEI

Life sciences giant Thermo Fisher Scientific ponied up $4.2 billion to buy Oregon-based FEI Co., gaining access to that company’s electron microscopy technology.

Read More »

FDA Approves First Implantable Device for Opioid Dependency

Titan Pharmaceuticals announced that the U.S. FDA approved Probuphine (buprenorphine) implant for long-term maintenance of opioid dependence.

Read More »

Gilead, Biogen, Jazz Pharma Subpoenaed as Feds Investigate Drugmaker-Charity Connections

Biogen, Gilead Sciences, and Jazz Pharmaceuticals are the latest drug companies to disclose that they have received federal subpoenas related to their relationships with charitable nonprofits. Although there are few details, both Gilead and Jazz did say that the subpoenas were issued by the U.S. Attorney for the District of Massachusetts.

Read More »

Embattled Valeant Reportedly Spurned a Takeover Offer from Takeda and TPG

In what some may have seen as “turnaround is fair play,” embattled drugmaker Valeant Pharmaceuticals – known for its aggressive growth by mergers and acquisitions strategy – rejected a takeover bid from Takeda Pharmaceuticals and TPG Capital Management LP before the Joe Papa era began, Business Insider reported.

Read More »

Genentech’s Gazyva Meets Primary Endpoint Early in Late-Stage Study

Interim data from a late-stage trial shows Genentech’s Gazyva for the treatment of untreated follicular lymphoma showed a significant difference in the staving off death or reducing the risk of disease progression when compared to Rituxan.

Read More »

Starboard Delivers Letter to Depomed Shareholders

Starboard Value LP, one of the largest shareholders of Depomed Inc. with an ownership interest in approximately 9.9% of Depomed’s outstanding shares, announced it has delivered an open letter to Depomed shareholders and intends to recommence the process for calling a Special Meeting of Depomed shareholders for removing and replacing the current Depomed Board of Directors with a modified slate of six highly qualified director nominees.

Read More »

Walgreens’ Execs Ignored Doubts in Theranos’ Technology in Fear of Deal Crumbling

Deerfield, Ill.-based Walgreens never vetted Theranos blood-testing technology before forming a partnership with the Palo-Alto, Calif. company, the Wall Street Journal reported.

Read More »

FORUM Pharma CEO Quits Amid Layoffs

FORUM Pharmaceuticals is laying off 77 people starting immediately, with another 12 job losses possible. There are unconfirmed rumors that the company may shut down.

Read More »

Page 1 of 912345...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom